Credit Suisse’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-370,000
| Closed | -$26.9M | – | 3883 |
|
|
2021
Q4 | $26.9M | Buy |
370,000
+113,800
| +44% | +$7.84M | 0.01% | 943 |
|
|
2021
Q3 | $17.9M | Buy |
256,200
+26,300
| +11% | +$1.85M | 0.01% | 1139 |
|
|
2021
Q2 | $15.8M | Sell |
229,900
-265,000
| -54% | -$17.7M | 0.01% | 1275 |
|
|
2021
Q1 | $32M | Sell |
494,900
-302,600
| -38% | -$19.5M | 0.02% | 918 |
|
|
2020
Q4 | $46.5M | Buy |
797,500
+82,100
| +11% | +$4.95M | 0.02% | 751 |
|
|
2020
Q3 | $45.2M | Buy |
715,400
+495,400
| +225% | +$34.4M | 0.03% | 650 |
|
|
2020
Q2 | $16.9M | Sell |
220,000
-89,800
| -29% | -$6.88M | 0.01% | 1022 |
|
|
2020
Q1 | $23.2M | Sell |
309,800
-207,400
| -40% | -$14.3M | 0.02% | 762 |
|
|
2019
Q4 | $33.6M | Sell |
517,200
-22,800
| -4% | -$1.48M | 0.02% | 745 |
|
|
2019
Q3 | $34.2M | Sell |
540,000
-117,600
| -18% | -$7.69M | 0.03% | 631 |
|
|
2019
Q2 | $44.4M | Buy |
657,600
+263,100
| +67% | +$17.3M | 0.04% | 494 |
|
|
2019
Q1 | $25.6M | Buy |
394,500
+72,500
| +23% | +$4.82M | 0.02% | 724 |
|
|
2018
Q4 | $20.1M | Sell |
322,000
-21,600
| -6% | -$1.51M | 0.02% | 791 |
|
|
2018
Q3 | $26.5M | Sell |
343,600
-8,500
| -2% | -$642K | 0.02% | 726 |
|
|
2018
Q2 | $24.9M | Sell |
352,100
-308,600
| -47% | -$21.8M | 0.02% | 719 |
|
|
2018
Q1 | $49.8M | Sell |
660,700
-70,700
| -10% | -$5.62M | 0.05% | 417 |
|
|
2017
Q4 | $52.4M | Sell |
731,400
-733,600
| -50% | -$55.7M | 0.05% | 406 |
|
|
2017
Q3 | $119M | Buy |
1,465,000
+455,000
| +45% | +$34.8M | 0.12% | 175 |
|
|
2017
Q2 | $71.5M | Sell |
1,010,000
-85,600
| -8% | -$5.7M | 0.07% | 286 |
|
|
2017
Q1 | $74.4M | Sell |
1,095,600
-143,300
| -12% | -$10.1M | 0.07% | 303 |
|
|
2016
Q4 | $88.7M | Sell |
1,238,900
-80,000
| -6% | -$5.95M | 0.09% | 231 |
|
|
2016
Q3 | $104M | Buy |
1,318,900
+973,900
| +282% | +$79.1M | 0.1% | 201 |
|
|
2016
Q2 | $28.8M | Buy |
345,000
+245,000
| +245% | +$21.7M | 0.03% | 600 |
|
|
2016
Q1 | $9.19M | Buy |
+100,000
| New | +$9.02M | 0.01% | 1161 |
|
|
2015
Q3 | – | Sell |
-547,600
| Closed | -$64.1M | – | 4345 |
|
|
2015
Q2 | $64.1M | Sell |
547,600
-631,500
| -54% | -$69M | 0.06% | 325 |
|
|
2015
Q1 | $116M | Buy |
1,179,100
+1,021,800
| +650% | +$104M | 0.12% | 181 |
|
|
2014
Q4 | $14.8M | Buy |
157,300
+107,300
| +215% | +$11.1M | 0.01% | 1033 |
|
|
2014
Q3 | $5.32M | Sell |
50,000
-54,000
| -52% | -$5.29M | ﹤0.01% | 1714 |
|
|
2014
Q2 | $8.62M | Buy |
+104,000
| New | +$8.1M | 0.01% | 1511 |
|
|
2014
Q1 | – | Sell |
-150,000
| Closed | -$11.3M | – | 4729 |
|
|
2013
Q4 | $11.3M | Buy |
150,000
+145,000
| +2,900% | +$10.1M | 0.01% | 1180 |
|
|
2013
Q3 | $314K | Buy |
+5,000
| New | +$299K | ﹤0.01% | 3777 |
|
Other funds holding GILD
Credit Suisse's GILD Position: Q1 2024 in Review
Credit Suisse reduced its Gilead Sciences (GILD) stake by 6.6% in Q1 2024, selling an estimated $15.8M and leaving 2,888,499 shares worth $212M. The position accounts for 0.2% of the portfolio, ranked #87.
Credit Suisse first reported a position in GILD in Q2 2013 and has held it in 44 quarters since. The position peaked at $705M in Q2 2015. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.
- Credit Suisse held 2,888,499 shares of Gilead Sciences worth $212M as of Q1 2024.
- Credit Suisse sold 205,129 Gilead Sciences shares in Q1 2024, an estimated $15.8M.
- Gilead Sciences made up 0.2% of Credit Suisse's portfolio in Q1 2024, its #87 holding.
- Credit Suisse first reported a position in Gilead Sciences in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Gilead Sciences position peaked at $705M in Q2 2015.
- 1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.